| Literature DB >> 26990518 |
Maxime Dougados1, Christophe Demattei2, Rosaline van den Berg3, Viet Vo Hoang4, Fabrice Thevenin5, Monique Reijnierse3, Damien Loeuille6, Antoine Feydy7, Pascal Claudepierre8, Désirée van der Heijde3.
Abstract
OBJECTIVE: To evaluate the rate of radiographic structural progression in the sacroiliac (SI) joints in patients with radiographic or nonradiographic axial spondyloarthritis (SpA), and to determine factors predisposing to such progression, over 2 years.Entities:
Mesh:
Year: 2016 PMID: 26990518 PMCID: PMC5129505 DOI: 10.1002/art.39666
Source DB: PubMed Journal: Arthritis Rheumatol ISSN: 2326-5191 Impact factor: 10.995
Baseline characteristics of the SpA patientsa
| Entire DESIR cohort (n = 708) | 2‐year completers (n = 595) | 2‐year completers with available imaging data (n = 449) | Radiographic status according to the modified New York criteria | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Positive at baseline | Negative at baseline | ||||||||
| Positive at 2 years (n = 116) | Negative at 2 years (n = 7) | All (n = 123) | Positive at 2 years (n = 16) | Negative at 2 years (n = 310) | All (n = 326) | ||||
| Age, mean ± SD years | 34 ± 8 | 34 ± 9 | 34 ± 9 | 34 ± 9 | 30 ± 7 | 33 ± 9 | 30 ± 10 | 35 ± 9 | 34 ± 9 |
| Sex, % female | 54 | 52 | 53 | 36 | 29 | 36 | 62 | 59 | 59 |
| B27 positive, % | 58 | 60 | 61 | 72 | 86 | 72 | 94 | 55 | 57 |
| Duration of symptoms, mean ± SD months | 18 ± 10 | 18 ± 11 | 18 ± 11 | 20 ± 10 | 17 ± 9 | 20 ± 10 | 18 ± 10 | 18 ± 11 | 18 ± 11 |
| Symptoms, % | |||||||||
| Arthritis | 21 | 21 | 21 | 17 | 29 | 18 | 6 | 24 | 23 |
| Enthesitis | 49 | 49 | 49 | 41 | 57 | 41 | 31 | 52 | 51 |
| Uveitis | 9 | 8 | 7 | 7 | 14 | 7 | 13 | 7 | 7 |
| IBD | 4 | 4 | 4 | 3 | 0 | 3 | 6 | 4 | 4 |
| BASDAI (0–100 scale), mean ± SD | 45 ± 20 | 44 ± 20 | 44 ± 19 | 40 ± 19 | 39 ± 20 | 40 ± 19 | 43 ± 18 | 45 ± 19 | 45 ± 19 |
| BASDAI ≥40, % | 60 | 60 | 59 | 48 | 57 | 49 | 50 | 64 | 63 |
| BASFI (0–100 scale), mean ± SD | 30 ± 23 | 30 ± 23 | 30 ± 22 | 29 ± 22 | 27 ± 21 | 29 ± 22 | 19 ± 21 | 31 ± 22 | 30 ± 22 |
| CRP, mean ± SD mg/liter | 8 ± 14 | 8 ± 14 | 8 ± 15 | 12 ± 17 | 24 ± 29 | 13 ± 18 | 8 ± 11 | 6 ± 13 | 6 ± 13 |
| Inflammation of the SI joints on MRI, % | 35.5 | 36.8 | 37.2 | 64.8 | 85.7 | 66.1 | 93.3 | 22.9 | 26.4 |
| ASDAS‐CRP, mean ± SD | 2.7 ± 1.0 | 2.7 ± 1.0 | 3.0 ± 1.0 | 3.0 ± 1.0 | 3.0 ± 1.0 | 3.0 ± 1.0 | 2.7 ± 1.0 | 2.7 ± 1.0 | 2.7 ± 1.0 |
| ASDAS‐CRP, % | |||||||||
| >3.5 | 19 | 20 | 19 | 22 | 40 | 23 | 14 | 17 | 17 |
| ≤3.5 to ≥2.1 | 52 | 50 | 51 | 52 | 60 | 52 | 64 | 50 | 50 |
| <2.1 to ≥1.3 | 22 | 21 | 21 | 19 | 0 | 18 | 14 | 22 | 22 |
| <1.3 | 8 | 8 | 9 | 7 | 0 | 7 | 7 | 11 | 10 |
| ASAS NSAID index, mean ± SD# | 56 ± 53 | 58 ± 53 | 59 ± 53 | 58 ± 51 | 33 ± 47 | 57 ± 51 | 70 ± 61 | 59 ± 53 | 59 ± 53 |
| Patients taking NSAIDs during the week preceding baseline, % | 70 | 71 | 72 | 75 | 57 | 74 | 62 | 72 | 71 |
| Patients taking a DMARD during the 6 months preceding baseline, % | 13 | 13 | 14 | 11 | 14 | 11 | 12 | 16 | 16 |
SpA = spondyloarthritis; DESIR = Devenir des Spondyloarthropathies Indifferérenciées Récentes; IBD = inflammatory bowel disease; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; CRP = C‐reactive protein; ASDAS‐CRP = Ankylosing Spondylitis Disease Activity Score using the CRP; DMARD = disease‐modifying antirheumatic drug.
Presence of radiographic sacroiliitis at baseline was defined as at least a unilateral grade 3 or a bilateral grade 2, as determined by the central readers.
Presence or history of the symptoms listed.
According to the Assessment of SpondyloArthritis international Society (ASAS) definition.
# The ASAS nonsteroidal antiinflammatory drug (NSAID) index was determined according to the ASAS proposal (ref. 21) and calculated based on the NSAID intake during the week preceding the baseline visit.
Figure 1Radiographic progression in the sacroiliac joint (SIJ) over a 2‐year follow‐up period in patients with recent‐onset (<3 years) nonradiographic axial spondyloarthritis (nr‐axial SpA) and patients with radiographic axial SpA (r‐axial SpA). mNY = modified New York.
Radiographic progression during the 2‐year follow‐up period with regard to baseline and 2‐year characteristics in patients with recent‐onset (<3 years) axial SpAa
| Radiographic progression | |||
|---|---|---|---|
| Yes (n = 16) | No (n = 310) |
| |
| Baseline characteristics | |||
| Age, mean ± SD | 30.0 ± 10.2 | 34.8 ± 8.6 | 0.02 |
| Sex, % male | 38 | 41 | 0.98 |
| Smokers, % | 56 | 32 | 0.08 |
| HLA–B27 positive, % | 94 | 56 | 0.006 |
| CRP, mg/liter | 8.3 ± 11.5 | 6.2 ± 13.5 | 0.04 |
| Inflammation of the SI joints on MRI, % | 94 | 23 | <0.001 |
| BASDAI, mean ± SD | 43.4 ± 18.5 | 45.0 ± 19.5 | 0.66 |
| 2‐year characteristics | |||
| BASDAI AUC, mean ± SD | 37 ± 21 | 39 ± 18 | 0.57 |
| ASAS NSAID index AUC, mean ± SD | 35 ± 22 | 40 ± 34 | 0.93 |
| Months of anti‐TNF therapy, mean ± SD | 3.3 ± 6.7 | 4.9 ± 8.3 | 0.49 |
Radiographic progression was defined as a switch from nonradiographic axial spondyloarthritis (SpA) (not fulfilling the modified New York criteria for structural damage) at baseline to radiographic axial SpA (fulfilling the modified New York criteria for structural damage) at 2 years. CRP = C‐reactive protein; SI = sacroiliac; MRI = magnetic resonance imaging; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; ASAS = Assessment of SpondyloArthritis international Society; NSAID = nonsteroidal antiinflammatory drug; AUC = area under the curve; anti‐TNF = anti–tumor necrosis factor.
By chi‐square test for binary variables and Student's t‐test or Mann‐Whitney Wilcoxon test for continuous variables.
Figure 2Risk of radiographic progression in the sacroiliac joint (SIJ) after a 2‐year follow‐up period in patients with recent‐onset axial spondyloarthritis (SpA) with regard to baseline parameters. Radiographic progression was defined as a switch from nonradiographic axial SpA to radiographic axial SpA according to the modified New York criteria. A, Smoking status at baseline. B, HLA–B27 positivity. C, Inflammation (subchondral bone edema according to the Assessment of SpondyloArthritis international Society/Outcome Measures in Rheumatology recommendations) of the SI joints on magnetic resonance imaging (MRI) at baseline, determined by a central reading procedure. Bars show the percent of patients. OR = odds ratio (with 95% confidence interval shown in brackets).